文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

作者信息

Zhao Lijun, Li Shuhong, Wei Xiaoyi, Qi Xuexiu, Guo Qiaoru, Shi Licai, Zhang Ji-Shuai, Li Jun, Liu Ze-Lin, Guo Zhi, Zhang Hongyu, Feng Jia, Shi Yuanyuan, Zhang Suping, Cao Yu J

机构信息

State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

The Shenzhen Pregene Biopharma Company, Ltd., Shenzhen 518118, China.

出版信息

Protein Cell. 2025 Mar 8;16(3):227-231. doi: 10.1093/procel/pwae034.

DOI:10.1093/procel/pwae034
PMID:38823002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11891134/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/b918fcc5382f/pwae034_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/b918fcc5382f/pwae034_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg

相似文献

[1]
A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

Protein Cell. 2025-3-8

[2]
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.

Oncol Lett. 2023-4-19

[3]
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.

Front Oncol. 2022-12-29

[4]
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

J Hematol Oncol. 2020-4-3

[5]
Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies.

Eur J Haematol. 2024-1

[6]
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.

J Immunother Cancer. 2025-4-30

[7]
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.

Cancer Immunol Immunother. 2023-9

[8]
Bispecific CAR T-cells for B-cell Malignancies.

Expert Opin Biol Ther. 2022-8

[9]
Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.

Leuk Lymphoma. 2023

[10]
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

Exp Hematol Oncol. 2022-3-22

引用本文的文献

[1]
Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape.

Mol Ther. 2025-8-8

[2]
Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.

Cancer Manag Res. 2025-7-15

[3]
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

Immunotargets Ther. 2025-6-27

[4]
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.

Front Immunol. 2025-5-21

本文引用的文献

[1]
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

Mol Ther. 2022-2-2

[2]
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

Nat Med. 2021-8

[3]
Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.

J Biol Chem. 2021-8

[4]
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.

Leukemia. 2021-10

[5]
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.

Sci Transl Med. 2021-3-24

[6]
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.

Signal Transduct Target Ther. 2021-2-25

[7]
Engineered T Cell Therapy for Cancer in the Clinic.

Front Immunol. 2019-10-11

[8]
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.

Int J Mol Sci. 2019-10-10

[9]
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Mol Ther Oncolytics. 2018-11-6

[10]
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2018-12-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索